دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project
Eric A. Secemsky, Neel Butala, Aishwarya Raja, Rohan Khera, Yongfei Wang, Jeptha P. Curtis, Thomas M. Maddox, Salim S. Virani, Ehrin J. Armstrong, Kendrick A. Shunk, Ralph G. Brindis, Deepak Bhatt, Robert W. Yeh
doi : 10.1161/CIRCINTERVENTIONS.120.010323
Circulation: Cardiovascular Interventions. 2021;14:e010323
Prior studies on the use of multivessel percutaneous coronary intervention (MV PCI) for patients with ST-segment–elevation myocardial infarction (STEMI) and multivessel coronary artery disease have yielded heterogeneous results. The recent COMPLETE trial (Complete Versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease After Early PCI for STEMI) demonstrated that MV PCI was superior to culprit-only PCI among patients with STEMI. It is unclear how these trial results apply to clinical decisions encountered in routine practice.
Multivessel Intervention in ST-Segment–Elevation Myocardial Infarction: Evidence-Based Practice or Guesswork?
Andrew M. Goldsweig, Vladimír Džavík
doi : 10.1161/CIRCINTERVENTIONS.121.011015
Circulation: Cardiovascular Interventions. 2021;14:e011015
Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction: Insights From the COMPLETE Trial
Payam Dehghani, Warren J. Cantor, Jia Wang, David A. Wood, Robert F. Storey, Roxana Mehran, Kevin R. Bainey, Robert C. Welsh, Josep Rodés-Cabau, Sunil Rao, Shahar Lavi, James L. Velianou, Madhu K. Natarajan, Antonios Ziakas, Vincenzo Guiducci, Francisco Fernández-Avilés, John A. Cairns, Shamir R. Mehta
doi : 10.1161/CIRCINTERVENTIONS.120.010458
Circulation: Cardiovascular Interventions. 2021;14:e010458
The COMPLETE trial (Complete Versus Culprit-Only Revascularization to Treat Multi-Vessel Disease After Early PCI for STEMI) demonstrated that staged nonculprit lesion percutaneous coronary intervention (PCI) reduced major cardiovascular events in patients with ST-segment–elevation myocardial infarction and multivessel coronary artery disease. It is unclear whether consistent benefit is observed in patients undergoing a pharmacoinvasive strategy compared with primary PCI.
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events
Seung-Jun Lee, Yong-Joon Lee, Byeong-Keuk Kim, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang
doi : 10.1161/CIRCINTERVENTIONS.121.010812
Circulation: Cardiovascular Interventions. 2021;14:e010812
In patients with acute coronary syndrome (ACS) with a high risk of ischemia, the impact of ticagrelor monotherapy after short-term dual antiplatelet therapy (DAPT) has not been clearly elucidated.
Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease
Christopher A. Rajkumar, Matthew Shun-Shin, Henry Seligman, Yousif Ahmad, Takayuki Warisawa, Christopher M. Cook, James P. Howard, Sashiananthan Ganesananthan, Laura Amarin, Caitlin Khan, Ayesha Ahmed, Alexandra Nowbar, Michael Foley, Ravi Assomull, Niall G. Keenan, Joban Sehmi, Thomas R. Keeble, John R. Davies, Kare H. Tang, Robert Gerber, Graham Cole, Peter O’Kane, Andrew S.P. Sharp, Ramzi Khamis, Gajen Kanaganayagam, Ricardo Petraco, Neil Ruparelia, Iqbal S. Malik, Sukhjinder Nijjer, Sayan Sen, Darrel P. Francis, Rasha Al-Lamee
doi : 10.1161/CIRCINTERVENTIONS.120.009891
Circulation: Cardiovascular Interventions. 2021;14:e009891
Physiological assessment with pressure wire pullback can characterize coronary artery disease (CAD) with a focal or diffuse pattern. However, the clinical relevance of this distinction is unknown. We use data from the ORBITA trial (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina) to test if the pattern of CAD predicts the placebo-controlled efficacy of percutaneous coronary intervention (PCI) on stress echocardiography ischemia and symptom end points.
Is There a Difference in Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Stable Coronary Artery Disease?
Daniell Edward Raharjo, Vijay Kunadian
doi : 10.1161/CIRCINTERVENTIONS.121.011013
Circulation: Cardiovascular Interventions. 2021;14:e011013
Efficacy and Safety of Percutaneous Pulmonary Artery Subtotal Occlusion and Chronic Total Occlusion Intervention in Chronic Thromboembolic Pulmonary Hypertension
Christian Gerges, Richard Friewald, Mario Gerges, Inbal Shafran, Roela Sadushi-Koliçi, Nika Skoro-Sajer, Bernhard Moser, Shahrokh Taghavi, Walter Klepetko, Irene M. Lang
doi : 10.1161/CIRCINTERVENTIONS.120.010243
Circulation: Cardiovascular Interventions. 2021;14:e010243
Balloon pulmonary angioplasty (BPA) is an emerging percutaneous therapy for patients with inoperable chronic thromboembolic pulmonary hypertension, and patients with mean pulmonary artery pressure ?30 mm?Hg have an excellent survival. Common vascular lesion types are ring-like stenoses (type A), web lesions (type B), subtotal occlusions (type C), chronic total occlusions (CTOs; type D), and tortuous lesions (type E). Occlusive lesions (ie, subtotal occlusions and CTOs) are the most challenging. Risk and benefit of pulmonary occlusive lesion intervention in chronic thromboembolic pulmonary hypertension has not been studied. We evaluated the impact of percutaneous pulmonary artery subtotal occlusion and CTO intervention on BPA treatment response.
Transcatheter Treatment of Secondary Tricuspid Regurgitation With Direct Annuloplasty: Results From a Multicenter Real-World Experience
Maria I. Körber, Melanie Landendinger, Muhammed Gerçek, Bo E. Beuthner, Kai P. Friedrichs, Miriam Puls, Stephan Baldus, Volker Rudolph, Claudius Jacobshagen, Martin Arnold, Roman Pfister
doi : 10.1161/CIRCINTERVENTIONS.120.010019
Circulation: Cardiovascular Interventions. 2021;14:e010019
Treatment options for secondary tricuspid regurgitation (TR) remain limited. Early real-world data of a new percutaneous direct annuloplasty system for tricuspid repair were examined.
Transcatheter Tricuspid Valve Annuloplasty: Show Me the Real-World Data
Elad Maor, Maurizio Taramasso
doi : 10.1161/CIRCINTERVENTIONS.121.011018
Circulation: Cardiovascular Interventions. 2021;14:e011018
Incidence and Clinical Significance of Worsening Tricuspid Regurgitation Following Surgical or Transcatheter Aortic Valve Replacement: Analysis From the PARTNER IIA Trial
Paul C. Cremer, Tom Kai Ming Wang, L. Leonardo Rodriguez, Brian R. Lindman, Yiran Zhang, Alan Zajarias, Rebecca T. Hahn, Stamatios Lerakis, S. Chris Malaisrie, Pamela S. Douglas, Philippe Pibarot, Lars G. Svensson, Samir Kapadia, Martin B. Leon, Wael A. Jaber, and on behalf of the PARTNER II Investigators
doi : 10.1161/CIRCINTERVENTIONS.120.010437
Circulation: Cardiovascular Interventions. 2021;14:e010437
Aortic valve replacement (AVR) is recommended for severe symptomatic aortic stenosis. However, the incidence of worsening tricuspid regurgitation (TR) following transcatheter compared with surgical AVR (TAVR, SAVR), and the impact of worsening TR on outcomes, is ill-defined. Accordingly, among patients randomized to TAVR or SAVR, we describe the differential incidence of worsening TR and its association with survival.
Impact of Mitral Annular Dilation on Edge-to-Edge Therapy With MitraClip-XTR
Felix Kreidel, Syed Zaid, Alexander R. Tamm, Tobias F. Ruf, Andres Beiras-Fernandez, Jenny Reinold, Martin Geyer, Jaqueline da Rocha e Silva, Katharina Schnitzler, Hell Michaela, Thomas Münzel, Gilbert H.L. Tang, Ralph Stephan von Bardeleben
doi : 10.1161/CIRCINTERVENTIONS.120.010447
Circulation: Cardiovascular Interventions. 2021;14:e010447
Mitral annular dilation has been shown to challenge successful edge-to-edge therapy with earlier MitraClip generations. Recently, third-generation MitraClip-XTR with extended clip arm length was introduced. We assessed the impact of annular dilation on residual mitral regurgitation (MR) after MitraClip-XTR repair and sought to identify cutoffs associated with suboptimal MR reduction.
Hypothermia for Reduction of Myocardial Reperfusion Injury in Acute Myocardial Infarction: Closing the Translational Gap
Mohamed El Farissi, Danielle C.J. Keulards, Jo M. Zelis, Marcel van ’t Veer, Frederik M. Zimmermann, Nico H.J. Pijls, Luuk C. Otterspoor
doi : 10.1161/CIRCINTERVENTIONS.120.010326
Circulation: Cardiovascular Interventions. 2021;14:e010326
Myocardial reperfusion injury—triggered by an inevitable inflammatory response after reperfusion—may undo a considerable part of the myocardial salvage achieved through timely percutaneous coronary intervention in patients with acute myocardial infarction. Because infarct size is strongly correlated to mortality and risk of heart failure, the importance of endeavors for cardioprotective therapies to attenuate myocardial reperfusion injury and decrease infarct size remains undisputed. Myocardial reperfusion injury is the result of several complex nonlinear phenomena, and for a therapy to be effective, it should act on multiple targets involved in this injury. In this regard, hypothermia remains a promising treatment despite a number of negative randomized controlled trials in humans with acute myocardial infarction so far. To turn the tide for hypothermia in patients with acute myocardial infarction, sophisticated solutions for important limitations of systemic hypothermia should continue to be developed. In this review, we provide a comprehensive overview of the pathophysiology and clinical expression of myocardial reperfusion injury and discuss the current status and possible future of hypothermia for cardioprotection in patients with acute myocardial infarction.
Lack of Association Between Percutaneous Coronary Intervention and Transcatheter Aortic Valve Replacement Outcomes in New York Hospitals
Rim Halaby, Jay Giri, Howard C. Herrmann, Taisei J. Kobayashi, Paul Fiorilli, Alexander C. Fanaroff, Ashwin S. Nathan
doi : 10.1161/CIRCINTERVENTIONS.121.010750
Circulation: Cardiovascular Interventions. 2021;14:e010750
Ten-Year Outcomes Following Percutaneous Left Atrial Appendage Closure in Patients With Atrial Fibrillation and Absolute or Relative Contraindications to Chronic Anticoagulation
Jules Mesnier, Ignacio Cruz-González, Vicente Peral, Luis Nombela-Franco, Xavier Freixa, Ana E. Laffond, Caterina Mas-Lladó, Angela McInerney, Ander Regueiro, Gilles O’Hara, Josep Rodés-Cabau
doi : 10.1161/CIRCINTERVENTIONS.121.010821
Circulation: Cardiovascular Interventions. 2021;14:e010821
